Paper Details

  1. Home
  2. Paper Details

Effectiveness of dapagliflozin versus comparators on renal endpoints in the real world: A multicentre retrospective study.

Author: , AnichiniRoberto, AvogaroAngelo, Del PratoStefano, FadiniGian Paolo, GattiAdriano, MancaMaria Laura, PennoGiuseppe, SoliniAnna

Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

Dapagliflozin significantly reduced albumin excretion rate (AER) in patients with type 2 diabetes mellitus compared to other glucose-lowering medications. Although there was a mild decline in estimated glomerular filtration rate (eGFR), there was no evidence of clinically relevant worsening in renal function.
Paper Details　
Original Abstract of the Article :
AIM: To evaluate the changes in renal endpoints in type 2 diabetes patients treated with dapagliflozin versus other glucose-lowering medications in routine clinical practice. MATERIALS AND METHODS: DARWIN-T2D was a retrospective study conducted at 46 outpatient diabetes clinics in Italy. An automat...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6585815/

データ提供：米国国立医学図書館（NLM）

Dapagliflozin: A Powerful Ally in the Battle Against Diabetic Kidney Disease

Diabetic kidney disease, a formidable foe that can lead to kidney failure, is like a creeping sandstorm, slowly encroaching on the body's vital organs. This study, published in the journal 'Diabetes & Metabolic Syndrome: Clinical Research & Reviews,' explores the potential of dapagliflozin, a SGLT2 inhibitor, to protect against this devastating complication.

A Powerful Weapon: Dapagliflozin Shows Promise in Protecting Kidneys

This study, like a fortress against a sandstorm, reveals the potential of dapagliflozin to shield the kidneys from the ravages of diabetic kidney disease. The study found that dapagliflozin significantly reduced albumin excretion rate (AER) and did not show evidence of worsening renal function. This finding is like discovering a sturdy shield in the desert, offering protection against the harsh elements.

A New Frontier in Kidney Protection: Understanding the Role of SGLT2 Inhibitors

This research, like a beacon of hope in the desert, opens up a new frontier in understanding the role of SGLT2 inhibitors in protecting kidney health. The findings suggest that dapagliflozin may offer a powerful weapon in the battle against diabetic kidney disease, potentially delaying or preventing the need for dialysis. This study encourages continued research into the potential benefits of SGLT2 inhibitors for patients with diabetes.

Dr. Camel's Conclusion

This study provides a compelling case for the use of dapagliflozin in protecting kidney function in patients with type 2 diabetes. While further research is needed to fully understand the long-term benefits and risks of this drug, the findings suggest that dapagliflozin may play a significant role in preventing or delaying the progression of diabetic kidney disease. This research is like a compass guiding us toward a better future for those battling this challenging complication of diabetes.
Date :
  1. Date Completed 2019-09-09
  2. Date Revised 2021-05-04
Further Info :

Pubmed ID

30136354

DOI: Digital Object Identifier

PMC6585815

Related Literature

Article Analysis
・Side Effects of dapagliflozin
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.